Skip to content
sellWeak cluster of 410b5-1 plan

Andrew Callos sold $943k of CYTK

EVP, Chief Commercial Officer at CYTOKINETICS INC. 20,900 shares at an average of $45.14, traded Mar 17, 2025, filed Mar 17, 2025.

Warning score
29
Value
$943k
20,900 shares
Holdings after
37,663
-36% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    Officer
    +15
  • Trade size
    $943k at market
    +24
  • Share of holdings sold
    Sold 36% of holdings
    +10
  • Cluster
    4 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

CYTKOct 9, 2026 · close 62.91
Since filing Mar 17, 2025: +40.1%SPY +40.0% · excess +0.1%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001127602-25-009691, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Mar 17, 2025MOption exercise
Common Stock10b5-1
+20,900$23.26$486k58,563Mar 17, 2025
Mar 17, 2025SOpen-market sale
Common Stock10b5-1
-20,900$45.14$943k37,663Mar 17, 2025
Mar 17, 2025MOption exercise
Non-Qualified Stock Option (Right to Buy)derivative10b5-1
-20,900$0.00$0129,000Mar 17, 2025

Related signals

Other insiders at CYTOKINETICS INC and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
0Weak
CYTKsell 210b5-1
CYTOKINETICS INC
Fady Ibraham Malik
EVP Research & Development
$215k
3,500 shares
-2%
23Weak
CYTKsell 310b5-1
CYTOKINETICS INC
Robert I Blum
President & CEO
$491k
7,500 shares
-3%
8Weak
CYTKsell 310b5-1
CYTOKINETICS INC
Fady Ibraham Malik
EVP Research & Development
$239k
3,500 shares
-2%
40Moderate
CYTKsell 410b5-1
CYTOKINETICS INC
Robert I Blum
President & CEO
$7.3M
105,426 shares
-27%
23Weak
CYTKsell 410b5-1
CYTOKINETICS INC
Robert E Landry
director
$72k
1,000 shares
-11%
18Weak
CYTKsell 410b5-1
CYTOKINETICS INC
Robert E Landry
director
$75k
1,000 shares
-10%
8Weak
CYTKsell 410b5-1
CYTOKINETICS INC
Fady Ibraham Malik
EVP Research & Development
$264k
3,500 shares
-2%
35Weak
CYTKsell 410b5-1
CYTOKINETICS INC
B Lynne Parshall
director
$357k
5,000 shares
-32%
16Weak
CYTKsell10b5-1
CYTOKINETICS INC
Robert I Blum
President & CEO
$169k
5,000 shares
-1%
16Weak
CYTKsell10b5-1
CYTOKINETICS INC
Robert I Blum
President & CEO
$156k
5,000 shares
-1%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Andrew Callos sold $943k of CYTK | InsiderTell